Aarkstore.com announces, The Latest market research report is available inits vast collection:Non-Small Cell Lung Cancer –...
company and industry-specific sources.- Coverage of products based on various stages of development ranging fromdiscovery ...
Bristol-Myers Squibb Company 160Boehringer Ingelheim GmbH 161F. Hoffmann-La Roche Ltd. 162Kyowa Hakko Kirin Co., Ltd. 163A...
Chronic Lymphocytic Leukemia (CLL) – Pipeline Review, H2 2012 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) ...
Upcoming SlideShare
Loading in …5
×

Non small cell lung cancer – pipeline review, h2 2012

666 views
622 views

Published on

Aarkstore Enterprise-Non small cell lung cancer – pipeline review, h2 2012

Published in: Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
666
On SlideShare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
3
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Non small cell lung cancer – pipeline review, h2 2012

  1. 1. Aarkstore.com announces, The Latest market research report is available inits vast collection:Non-Small Cell Lung Cancer – Pipeline Review, H2 2012You can also request for sample page of above mention reports onsample@aarkstore.comSummaryGlobal Markets Direct’s, Non-Small Cell Lung Cancer - Pipeline Review, GlobalMarkets Direct’s, Non-Small Cell Lung Cancer - Pipeline Review, H2 2012, providesan overview of the indication’s therapeutic pipeline. This report providesinformation on the therapeutic development for Non-Small Cell Lung Cancer,complete with latest updates, and special features on late-stage and discontinuedprojects. It also reviews key players involved in the therapeutic development forNon-Small Cell Lung Cancer. Non-Small Cell Lung Cancer - Pipeline Review, HalfYear is built using data and information sourced from Global Markets Direct’sproprietary databases, Company/University websites, SEC filings, investorpresentations and featured press releases from company/university sites andindustry-specific third party sources, put together by Global Markets Direct’s team.Note*: Certain sections in the report may be removed or altered based on theavailability and relevance of data for the indicated disease.Scope- A snapshot of the global therapeutic scenario for Non-Small Cell Lung Cancer.- A review of the Non-Small Cell Lung Cancer products under development bycompanies and universities/research institutes based on information derived from
  2. 2. company and industry-specific sources.- Coverage of products based on various stages of development ranging fromdiscovery till registration stages.Reasons to buy- Identify and understand important and diverse types of therapeutics underdevelopment for Non-Small Cell Lung Cancer.- Identify emerging players with potentially strong product portfolio and designeffective counter-strategies to gain competitive advantage.Table of contents:List of Tables 25List of Figures 33Introduction 34Global Markets Direct Report Coverage 34Non-Small Cell Lung Cancer Overview 35Therapeutics Development 36An Overview of Pipeline Products for Non-Small Cell Lung Cancer 36Non-Small Cell Lung Cancer Therapeutics under Development by Companies 38Non-Small Cell Lung Cancer Therapeutics under Investigation byUniversities/Institutes 50Late Stage Products 72Comparative Analysis 72Mid Clinical Stage Products 73Comparative Analysis 73Early Clinical Stage Products 74Comparative Analysis 74Discovery and Pre-Clinical Stage Products 75Comparative Analysis 75Non-Small Cell Lung Cancer Therapeutics – Products under Development byCompanies 76Non-Small Cell Lung Cancer Therapeutics – Products under Investigation byUniversities/Institutes 101Companies Involved in Non-Small Cell Lung Cancer Therapeutics Development 160
  3. 3. Bristol-Myers Squibb Company 160Boehringer Ingelheim GmbH 161F. Hoffmann-La Roche Ltd. 162Kyowa Hakko Kirin Co., Ltd. 163Abbott Laboratories 164Biogen Idec Inc. 165Helix BioPharma Corp. 166Amgen Inc. 167Sanofi-Aventis 168List of FiguresList of Tables are also include.For more related Reports Plz follow The link:Pipeline Review, H2 2012http://www.aarkstore.com/search/viewresults.asp?search=Pipeline Review, H22012&PubId=&pagenum=1 Liver Cancer – Pipeline Review, H2 2012 Non-Small Cell Lung Cancer – Pipeline Review, H2 2012 Asthma – Pipeline Review, H2 2012 Multiple Sclerosis – Pipeline Review, H2 2012 Gastrointestinal Tract Cancer – Pipeline Review, H2 2012 Diabetes – Pipeline Review, H2 2012
  4. 4. Chronic Lymphocytic Leukemia (CLL) – Pipeline Review, H2 2012 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline Review,H2 2012 Graft Versus Host Disease (GVHD) – Pipeline Review, H2 2012 Malaria – Pipeline Review, H2 2012 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections – Pipeline Review,H2 2012 Dermatitis – Pipeline Review, H2 2012Search More Reports Related to This Category :Pharmaceuticals and Healthcarehttp://www.aarkstore.com/search/viewresults.asp?search=Pharmaceuticals andHealthcare&PubId=&pagenum=1For More details Plz do contact :Aarkstore EnterpriseLavanyaPhone:08149852585Email: enquiry@aarkstore.com

×